ISWM
NRIX icon

Intesa Sanpaolo Wealth Management’s Nurix Therapeutics NRIX Stock Holding History

Intesa Sanpaolo Wealth Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$39.1K Hold
1,610
– – 0.01% 241
2026
Q1 		$25K Hold
1,610
– – 0.01% 245
2025
Q4 		$30.5K Buy
+1,610
New +$23.1K 0.01% 229

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Intesa Sanpaolo Wealth Management's NRIX Position: Q2 2026 in Review

Intesa Sanpaolo Wealth Management held its Nurix Therapeutics (NRIX) position steady in Q2 2026 at 1,610 shares worth $39.1K. The position accounts for 0.01% of the portfolio, ranked #241.

Intesa Sanpaolo Wealth Management first reported a position in NRIX in Q4 2025 and has held it in 3 quarters since. 211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Intesa Sanpaolo Wealth Management held 1,610 shares of Nurix Therapeutics worth $39.1K as of Q2 2026.
  • Intesa Sanpaolo Wealth Management left its Nurix Therapeutics share count unchanged in Q2 2026.
  • Nurix Therapeutics made up 0.01% of Intesa Sanpaolo Wealth Management's portfolio in Q2 2026, its #241 holding.
  • Intesa Sanpaolo Wealth Management first reported a position in Nurix Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Intesa Sanpaolo Wealth Management's 13F filing for Q2 2026, filed 23 Jul 2026.